Taking stock of the drug industry, from the lab to the medicine chest STAT+: Here's what Democrats changed in their latest drug pricing bill By Rachel Cohrs Sarah Silbiger/Getty Images Senate Democrats have put final tweaks on their drug pricing proposal, as they race to achieve one of their signature domestic policy promises Read More STAT+: With 'do-over' NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition By Adam Feuerstein Hyacinth Empinado/STAT An extensive re-analysis of a large clinical trial involving its experimental treatment once again achieved its primary efficacy goal. Read More STAT+: In the search for an ARPA-H director, the White House is zeroing in on DARPA veterans By Lev Facher Michael Reynolds/AP Francis Collins is making progress in finding a director for ARPA-H, and he’s turned to a natural proving ground for candidates: DARPA. Read More Sponsor content by STAT+ The next generation of STAT Wunderkinds The search continues! STAT is on the lookout for the most impressive young minds in science, to give them the recognition they deserve. Nominate someone today. Opinion: Hospitals and for-profit PBMs are diverting billions in 340B savings from patients in need By Ted Okon APStock Nonprofit hospitals and for-profit 340B contract pharmacies are diverting billions of dollars that should be helping patients in need. Read More Listen: VC malaise, FDA confusion, & yet another Alzheimer's debate By Damian Garde and Adam Feuerstein STAT's Allison DeAngelis joins us to explain how the prolonged downturn for biotech stocks is stoking anxiety among venture capitalists. Read More Thursday, July 7, 2022 1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser
No comments